- The disease
- Primary axillary hyperhidrosis is a condition characterised by excessive sweating from the underarms that is not caused by another underlying medical condition or medication. It affects daily activities and quality of life. The condition is chronic and can be difficult to manage with standard over-the-counter antiperspirants alone. Prevalence estimates and epidemiological figures for this indication are .
- What the asset is trying to do
- SOFDRA (sofpironium bromide) is a topical gel classified as a small molecule. It belongs to the anticholinergic class, which works by blocking muscarinic receptors in sweat glands to reduce sweat production when applied to the skin. The product is designed for local application to limit systemic absorption, which is a characteristic that distinguishes it from oral anticholinergic agents (per the SOFDRA US prescribing information ).
- What the trial is measuring, and why it matters
- The pivotal Phase 3 trials (NCT03948646 and NCT03836287) enrolled approximately 350 participants each and were completed in 2021 (per ClinicalTrials.gov NCT03948646 and NCT03836287). Endpoints assessed in hyperhidrosis trials typically include validated patient-reported outcome scales for sweat severity and gravimetric measures of sweat production, though the specific primary endpoints for these trials are . Understanding these endpoints matters because regulatory approval in dermatology conditions relies on demonstrating both a statistically significant and clinically meaningful reduction in symptom burden.
- Efficacy benchmarks in this setting
- In the approved comparator landscape for axillary hyperhidrosis, glycopyrronium cloth (Qbrexza), an anticholinergic wipe, received US FDA approval in 2018 (per FDA approval records). Specific response rates, Hyperhidrosis Disease Severity Scale (HDSS) responder rates, and gravimetric sweat reduction figures achieved by approved therapies in this setting are . Early-stage or single-arm figures from this asset's development programme are not statistically comparable to results from controlled pivotal trials of approved products.
- Commercial context
- SOFDRA (sofpironium bromide 15% gel) received US FDA approval for primary axillary hyperhidrosis in adults and paediatric patients aged nine years and older (per ). Botanix has disclosed a term sheet agreement with a second active pharmaceutical ingredient (API) supplier (per ASX announcement, 15 April 2026) and a renegotiation of an existing API supply agreement (per ASX announcement, 29 March 2026). SOFDRA is described as a lead commercial asset for Botanix Pharmaceuticals. Disclosed deal values, royalty terms, and US commercialisation partnership details are .